Publications by authors named "J Martin Broto"
Background: Herein, we present the results of the phase 2 IMMUNOSARC study (NCT03277924), investigating sunitinib and nivolumab in adult patients with advanced bone sarcomas (BS).
Methods: Progressing patients with a diagnosis of BS were eligible. Treatment was comprised of sunitinib (37.
Article Synopsis
- Tenosynovial giant cell tumour (TGCT) is a rare tumor that grows around joints and tendons, with two types: nodular (less aggressive) and diffuse (more aggressive).
- TGCT can lead to chronic pain and negatively affect a person's quality of life, though it's not usually life-threatening.
- A global meeting in June 2022 brought together experts and patients to establish better treatment guidelines for TGCT, given the challenges in making consistent treatment choices worldwide.
Background: The Complexity INdex in SARComas (CINSARC) is a transcriptional signature derived from the expression of 67 genes involved in mitosis control and chromosome integrity. This study aims to assess CINSARC value of in an independent series of high-risk patients with localized soft tissue sarcoma (STS) treated with preoperative chemotherapy within a prospective, randomized, phase III study (ISG-STS 1001).
Patients And Methods: Patients with available pre-treatment samples, treated with 3 cycles of either standard (ST) preoperative or histotype-tailored (HT) chemotherapy, were scored according to CINSARC (low-risk, C1; high-risk, C2).
Background: We retrospectively investigated the role of (neo)adjuvant chemotherapy in patients with primary, localized angiosarcoma.
Methods: We selected all patients with primary, localized angiosarcoma, who had received radical surgery between January 2005 and December 2019 at 33 European sarcoma reference centers. The primary objective was to compare the outcome of patients who received (neo)adjuvant chemotherapy versus those who did not, in terms of overall survival (OS), disease-free survival (DFS) and distant metastasis-free survival (DMFS).